Looking at this filing, I need to identify the key facts. Generate Biomedicines, Inc. (NASDAQ:GENB) filed a 10-Q for the quarterly period ended September 30, 2026. The filing content provided is primarily the cover page, table of contents, and forward-looking statements cautionary language. There is limited financial data in the extracted text, but the cover page provides enough substantive disclosure (company identity, share count, filer status, exchange listing, fiscal period) to clear the 150-word threshold for substantive content.

Generate Biomedicines, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 12, 2026, covering the company's third quarter financial results and disclosures.

Key Highlights

  • Shares outstanding: As of October 29, 2026, the registrant had 129,096,666 shares of common stock, $0.001 par value per share, outstanding.
  • Exchange listing: Common stock is listed on The Nasdaq Global Select Market under the trading symbol GENB.
  • Filer classification: Generate Biomedicines is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company under SEC definitions.
  • Shell company status: The registrant indicated it is not a shell company as defined in Rule 12b-2 of the Exchange Act.
  • Filing compliance: The registrant confirmed it has filed all required reports during the preceding 12 months and has submitted all required Interactive Data Files electronically.
  • EGC transition period: The company has not elected to use the extended transition period for complying with new or revised financial accounting standards under Section 13(a) of the Exchange Act.

Generate Biomedicines Reports Third Quarter 2026 Status and Corporate Standing

Generate Biomedicines, Inc., a Delaware-incorporated biotechnology company headquartered at 101 South Street, Suite 900, Somerville, MA 02143, submitted its quarterly report on Form 10-Q for the period ended September 30, 2026, to the SEC. The company, which operates under Commission File Number 001-43165, holds its common stock listing on The Nasdaq Global Select Market under ticker NASDAQ:GENB. According to the filing, the company had 129,096,666 shares of common stock outstanding as of October 29, 2026.

The filing identifies Generate Biomedicines as a non-accelerated filer, a smaller reporting company, and an emerging growth company, all as defined under Rule 12b-2 of the Exchange Act. These classifications affect the regulatory and reporting requirements applicable to the company. The registrant disclosed it has not elected to use the extended transition period available to emerging growth companies for adopting new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.

According to the filing, Generate Biomedicines uses artificial intelligence in its drug discovery and development process and maintains what it refers to as "The Generate Platform." The forward-looking statements section of the quarterly report references the company's product candidates, nonclinical studies, clinical trials, and collaboration and licensing agreements as areas subject to uncertainty. The filing notes that all forward-looking statements are subject to known and unknown risks and uncertainties and that "actual results may be materially different from any future results expressed or implied by these forward-looking statements," according to the company's own cautionary language.

What Was Disclosed

Generate Biomedicines, Inc. filed a 10-Q for the quarter ended September 30, 2026, disclosing 129,096,666 shares outstanding as of October 29, 2026, its listing on NASDAQ:GENB, and its classification as a non-accelerated filer, smaller reporting company, and emerging growth company.